Hidromorfona Aristo (Hydromorphone Hydrochloride)

Hidromorfona Aristo is indicated for the management of severe pain that requires an opioid analgesic.

• Severe acute pain, such as that following trauma or surgery.
• Cancer‑related pain that is not adequately controlled by non‑opioid agents.
• Post‑operative pain after major surgical procedures.
• Pain associated with serious injuries or burns.
• Situations where rapid and reliable analgesia is needed under close medical supervision.
• Pain in palliative care settings where strong opioid therapy is appropriate.

• Hydromorphone hydrochloride exerts its analgesic effect by acting as a full agonist at the µ‑opioid receptors located in the central nervous system. Binding to these G‑protein‑coupled receptors inhibits adenylate cyclase activity, reduces calcium influx, and increases potassium efflux, leading to hyperpolarization of neurons and decreased transmission of nociceptive signals. The overall effect is modulation of neurotransmitter release that contributes to analgesia.

Like other opioid analgesics, Hidromorfona Aristo may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common

• Constipation, which may require dietary adjustments or laxatives.
• Nausea or vomiting, especially when therapy is initiated.
• Drowsiness or sedation that can affect alertness.
• Dry mouth and reduced saliva production.

Serious

• Respiratory depression, potentially life‑threatening, especially at high doses.
• Severe hypotension or cardiovascular collapse.
• Development of physical dependence or withdrawal syndrome upon abrupt discontinuation.

When prescribing Hidromorfona Aristo, clinicians should evaluate patient-specific factors and monitor for safety concerns.

• Assess respiratory function before initiating therapy and during dose adjustments.
• Use the lowest effective dose for the shortest duration necessary.
• Avoid use in patients with known hypersensitivity to hydromorphone or other opioids.
• Exercise caution in individuals with a history of substance use disorder.
• Monitor for signs of sedation, confusion, or impaired cognition, especially in the elderly.
• Consider alternative analgesics in patients with severe hepatic or renal impairment.

Hydromorphone can interact with several medications, altering its efficacy or increasing the risk of adverse effects.

Avoid

• Concomitant use with other central nervous system depressants such as benzodiazepines, barbiturates, or alcohol, which can markedly increase respiratory depression risk.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may raise hydromorphone plasma concentrations.

Use with caution

• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) that can affect metabolism.
• Other opioid analgesics, which may compound sedative effects.
• Anticholinergic agents, which can exacerbate constipation.
• Medications that prolong QT interval, requiring cardiac monitoring.